BIOHAVEN LTD
BHVNNYSE🏆 #1996 by market capEarnings Nov 9US Equity
$13.29▲ $0.01 (+0.11%)
After hours · at closeTrack BHVN
Get earnings, price moves & breaking news on Telegram
24h▲ 0.1%
7d▼ 10.6%
14d▲ 7.6%
30d▼ 13.8%
ytd▲ 17.8%
1y▼ 9.4%
🏦Market Cap
$2.00B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
48
Weak
Trading Snapshot
- Day Range
- $13.22 – $13.40
- 52-Week Range
- $7.48 – $18.57
- Volume
- $1.88B
- Avg Volume
- $1.63B
- Shares Outstanding
- 150.6M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $141M
- Last Q Revenue
- $33M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-4.64
- Dividend Yield
- —
- Dilution (1yr)
- +18.9%
Why Investors Own BHVN
- ✓High-growth profile — revenue up +55.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIOHAVEN LTD
BHVNFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$745M▼ −15.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$610M▲ +4.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
120.2M▲ +18.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$55M▼ −$117M YoY
StockOtter · stockotter.spaceAbout BIOHAVEN LTD
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100
Analyst Ratings
ⓘConsensus
Buy
23 analysts
Strong Buy7
Buy11
Hold4
Sell1
Strong Sell0
Ratings as of Sep 2026
Latest News & Updates
🚀
CNBC·2h ago
BIOHAVEN LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift BHVN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
BIOHAVEN LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.